Algert Global LLC Has $7.70 Million Stock Holdings in Kura Oncology, Inc. (NASDAQ:KURA)

Algert Global LLC increased its holdings in shares of Kura Oncology, Inc. (NASDAQ:KURA - Free Report) by 224.6% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 883,703 shares of the company's stock after acquiring an additional 611,427 shares during the period. Algert Global LLC owned about 1.14% of Kura Oncology worth $7,697,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the business. China Universal Asset Management Co. Ltd. boosted its holdings in Kura Oncology by 11.9% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 16,489 shares of the company's stock valued at $144,000 after purchasing an additional 1,750 shares in the last quarter. Rhumbline Advisers grew its position in Kura Oncology by 2.0% in the fourth quarter. Rhumbline Advisers now owns 99,991 shares of the company's stock valued at $871,000 after acquiring an additional 1,923 shares during the period. Harbor Capital Advisors Inc. raised its stake in Kura Oncology by 4.4% during the fourth quarter. Harbor Capital Advisors Inc. now owns 49,371 shares of the company's stock worth $430,000 after acquiring an additional 2,076 shares in the last quarter. Teacher Retirement System of Texas lifted its holdings in shares of Kura Oncology by 19.9% during the fourth quarter. Teacher Retirement System of Texas now owns 13,749 shares of the company's stock valued at $120,000 after acquiring an additional 2,285 shares during the period. Finally, MetLife Investment Management LLC boosted its stake in shares of Kura Oncology by 6.6% in the 4th quarter. MetLife Investment Management LLC now owns 44,828 shares of the company's stock valued at $390,000 after purchasing an additional 2,776 shares in the last quarter.

Kura Oncology Trading Down 3.8 %

NASDAQ:KURA traded down $0.23 on Friday, hitting $5.77. 742,242 shares of the stock were exchanged, compared to its average volume of 1,172,809. The company has a debt-to-equity ratio of 0.02, a quick ratio of 11.47 and a current ratio of 11.47. Kura Oncology, Inc. has a 52 week low of $5.41 and a 52 week high of $23.48. The stock has a market capitalization of $499.54 million, a price-to-earnings ratio of -2.44 and a beta of 0.50. The company's 50-day moving average price is $6.57 and its 200 day moving average price is $9.18.

Kura Oncology (NASDAQ:KURA - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The company reported ($0.66) earnings per share for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.15). The company had revenue of $14.11 million for the quarter, compared to analyst estimates of $39.08 million. On average, equities research analysts forecast that Kura Oncology, Inc. will post -2.44 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on KURA shares. HC Wainwright reissued a "buy" rating and set a $40.00 price target on shares of Kura Oncology in a report on Monday, April 28th. Barclays reduced their target price on Kura Oncology from $32.00 to $11.00 and set an "overweight" rating on the stock in a report on Friday, May 2nd. JMP Securities reaffirmed a "market outperform" rating and set a $28.00 price target on shares of Kura Oncology in a report on Tuesday, April 29th. BTIG Research lowered Kura Oncology from a "buy" rating to a "neutral" rating in a research note on Thursday, February 6th. Finally, Wedbush restated an "outperform" rating and issued a $36.00 target price on shares of Kura Oncology in a research note on Tuesday, April 8th. Four research analysts have rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $23.89.

Kura Oncology Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.